Vitamin D status and HIV-related complications in children and young adults

儿童和年轻人的维生素 D 状况和 HIV 相关并发症

• 批准号: 8263565
• 负责人: Allison Ross Eckard
• 金额: $ 12.61万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-01-02 至 2016-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8263565
• 关键词: 25-hydroxycholecalciferol-24-hydroxylase; 25-hydroxyvitamin D; Address; Adolescent; Adult; Adverse effects; Affect; African American; Age; Anti-Retroviral Agents; Biological Markers; Blood; C-reactive protein; CAP18 lipopolysaccharide-binding protein; CD4 Lymphocyte Count; Cardiovascular Diseases; Cardiovascular system; Cell Adhesion; Cell Adhesion Molecules; Child; Childhood; Cholecalciferol; Chronic; Clinical Nutrition; Clinical Research; Commit; Communicable Diseases; Comorbidity; Data; Development; Disease; Disease Progression; Dose; Double-Blind Method; Enzymes; Etiology; Functional disorder; Future; General Population; HIV; HIV Infections; Health; Health Status; High Prevalence; Immune; Immune System Diseases; Individual; Inflammation; Inflammatory; Institute of Medicine (U.S.); Interleukin-6; Learning; Life; Malignant Neoplasms; Mentors; Metabolic; Metabolism; Methods; Myocardial; Oral; Osteoporosis; Overweight; Participant; Patients; Pharmaceutical Preparations; Physicians; Physiologic pulse; Physiological; Plasma; Play; Population; Population Group; Primary Prevention; Process; Public Health; Randomized Controlled Clinical Trials; Randomized Controlled Trials; Recruitment Activity; Regimen; Reporting; Research; Research Methodology; Research Personnel; Risk; Risk Assessment; Role; Scientist; Serum; Specialist; Supplementation; Surrogate Markers; TNFR-Fc fusion protein; Testing; Thick; Time; Training; Vascular Cell Adhesion Molecule-1; Vascular Smooth Muscle; Vitamin D; Vitamin D Deficiency; Vitamins; antimicrobial; antiretroviral therapy; arm; arterial stiffness; cardiovascular disorder risk; cost effective; cytokine; disorder prevention; efficacy testing; experience; high risk; immune function; improved; intercellular cell adhesion molecule; intima media; multidisciplinary; patient population; response; restoration; young adult

DESCRIPTION (provided by applicant): Vitamin D is critical in many physiologic and pathophysiologic processes including inflammatory status, immune function, and cardiovascular health. Vitamin D deficiency is widespread among HIV-infected adults and children. This is particularly alarming since there is a higher risk than the general population for complications like osteoporosis, non-AIDS-defining malignancies, and cardiovascular disease (CVD) - all diseases associated with vitamin D deficiency. It is not known how much vitamin D deficiency heightens the risk of complications like CVD, affects immune function and disease progression, or interferes with optimal treatment in the HIV population. The impact of vitamin D deficiency in the HIV population may be compounded even further since the etiology of HIV-related complications like CVD is thought to be related in part to inflammation and detrimental endothelial effects associated with chronic HIV infection-similar proposed mechanisms as vitamin D deficiency. Data suggest that optimal vitamin D status may be protective against these HIV-related complications, and optimizing vitamin D status with oral supplementation in HIV-infected individuals may improve the risk of HIV-related complications by decreasing inflammation and/or improving endothelial dysfunction, and may improve immune function even in individuals on antiretroviral therapy. Developing suitable repletion strategies is crucial to maximizing health status, particularly in HIV-infected children and young adults, where an opportunity exists for disease prevention. However, the best method of vitamin D repletion is not known, and data suggest that some antiretroviral medications interfere with vitamin D metabolism. Thus, we hypothesize that (1) optimizing vitamin D status to the current Institute of Medicine's (IOM) suggested 25-hydroxyvitamin D (25(OH)D) concentration of e20 ng/mL improves CVD risk, inflammation, and CD4 cell counts in HIV-infected individuals, (2) increasing 25(OH)D concentrations to >30 ng/mL improves CVD risk and inflammation to a greater degree than increasing eto 20 ng/mL (the concentration some experts consider optimal for cardiovascular health), and (3) a "high dose" of oral vitamin D is necessary to achieve 25(OH)D concentrations >30 ng/mL. These hypotheses will be addressed by determining the longitudinal relationships between serum 25(OH)D concentrations, carotid intima-media thickness, pulse wave velocity, pro-inflammatory biomarkers, and CD4 cell counts in HIV-infected children and young adults in a double-blinded, randomized-controlled trial of three different vitamin D dosing regimens given over 24 months in HIV-infected children and young adults (ages 10-25 years) with vitamin D deficiency (25(OH)D <20 ng/mL). We will also evaluate the 25(OH)D concentrations from each arm after 6, 12, and 24 months of supplementation, in order to determine a dose-response relationship. These findings could have a sizable impact on health in this population, since vitamin D therapy is inexpensive and associated with few adverse side effects. The PI is an exceptional candidate who is a pediatric infectious diseases specialist with a proven research focus in the metabolic and cardiovascular complications of HIV. She is mentored by a committed, multidisciplinary team of senior investigators with extensive experience in both mentoring and in the research methodologies relevant to this proposal. Future training in all aspects of clinical research, cardiovascular disease risk assessment, and clinical nutrition is planned to facilitate the PI's development into a successful independent physician scientist. PUBLIC HEALTH RELEVANCE: In most studies, HIV-infected individuals have a higher prevalence of vitamin D deficiency compared to uninfected individuals. Vitamin D deficiency may contribute to some of the long-term complications of HIV infection, such as cardiovascular disease and increased inflammation. This proposal will advance our understanding of whether correction of vitamin D deficiency affects the risk of these HIV-related complications and/or improves CD4 cell counts.

描述（由申请人提供）：维生素D在许多生理和病理生理过程中至关重要，包括炎症状态、免疫功能和心血管健康。维生素D缺乏症在感染艾滋病毒的成人和儿童中普遍存在。这一点尤其令人担忧，因为与普通人群相比，骨质疏松症、非艾滋病定义的恶性肿瘤和心血管疾病（CVD）等并发症的风险更高-所有这些疾病都与维生素D缺乏有关。目前尚不清楚维生素D缺乏会增加CVD等并发症的风险，影响免疫功能和疾病进展，或干扰HIV人群的最佳治疗。HIV人群中维生素D缺乏的影响可能会进一步加剧，因为HIV相关并发症（如CVD）的病因被认为部分与慢性HIV感染相关的炎症和有害内皮效应有关-与维生素D缺乏类似的机制。数据表明，最佳的维生素D状态可能对这些HIV相关并发症具有保护作用，并且在HIV感染者中口服补充维生素D可以通过减少炎症和/或改善内皮功能障碍来改善HIV相关并发症的风险，甚至可以改善抗逆转录病毒治疗个体的免疫功能。制定适当的补充营养战略对于最大限度地改善健康状况至关重要，特别是对感染艾滋病毒的儿童和年轻人而言，这是预防疾病的机会。然而，补充维生素D的最佳方法尚不清楚，数据表明一些抗逆转录病毒药物会干扰维生素D代谢。因此，我们假设（1）将维生素D状态优化为当前医学研究所（IOM）建议的25-羟基维生素D（25（OH）D）浓度e20 ng/mL，可改善HIV感染个体的CVD风险、炎症和CD 4细胞计数，（2）将25（OH）D浓度增加至>30 ng/mL比将25（OH）D浓度增加至20 ng/mL更大程度地改善CVD风险和炎症。（一些专家认为对心血管健康最佳的浓度），和（3）“高剂量”的口服维生素D对于实现25（OH）D浓度>30 ng/mL是必要的。这些假设将通过在双盲、双盲、双盲的研究中确定艾滋病毒感染儿童和年轻人的血清25（OH）D浓度、颈动脉内膜中层厚度、脉搏波速度、促炎生物标志物和CD 4细胞计数之间的纵向关系来解决。在HIV感染的儿童和年轻人中给予三种不同维生素D给药方案超过24个月的随机对照试验（年龄10-25岁）患有维生素D缺乏症（25（OH）D <20 ng/mL）。我们还将在补充6、12和24个月后评估每组的25（OH）D浓度，以确定剂量-反应关系。这些发现可能会对这一人群的健康产生相当大的影响，因为维生素D治疗价格低廉，而且副作用很少。PI是一位杰出的候选人，他是儿科传染病专家，研究重点是HIV的代谢和心血管并发症。她由一个致力于多学科的高级研究人员团队指导，该团队在指导和与此提案相关的研究方法方面拥有丰富的经验。计划在临床研究，心血管疾病风险评估和临床营养的各个方面进行未来培训，以促进PI发展成为成功的独立医生科学家。 公共卫生关系：在大多数研究中，艾滋病毒感染者与未感染者相比，维生素D缺乏症的患病率更高。维生素D缺乏可能导致艾滋病毒感染的一些长期并发症，如心血管疾病和炎症增加。这项建议将促进我们对维生素D缺乏症的纠正是否会影响这些HIV相关并发症的风险和/或改善CD 4细胞计数的理解。